Market research
AGLE Aeglea Bio Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- 17.5
- Dividend yield
- 0.0%
- Beta
- 2.57
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US00773J1034
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- 17.5
- Dividend yield
- 0.0%
- Beta
- 2.57
About
About Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AGLE discussion.
5 years, 4 months ago
Aeglea BioTherapeutics, Inc is currently in a long term downtrend where the price is trading 7.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Aeglea BioTherapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 5.7% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.8% to $-18M since the same quarter in the previous year.
Based on the above factors, Aeglea BioTherapeutics, Inc gets an overall score of 1/5.